|
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Clinical research trials and Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients. Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients clinical trial. Subjects frequently obtain the most expert healthcare possible for their Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients  Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
For Condition: Candidiasis, Oral,HIV Infections
Status: Completed
Sponsor(s): Schering-Plough ,
Synopsis: The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush. SCH 56592 is a new drug that will be compared to fluconazole.
Details: Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria You may be eligible for this study if you: - Are at least 18 years old. - Are HIV-positive. - Have thrush (oropharyngeal candidiasis). - Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms). - Are able to take study medication and return for clinic visits during the study. - Are expected to live for at least 2 months. Exclusion Criteria You will not be eligible for this study if you: - Have received protease inhibitors for the first time within 30 days prior to study entry. - Have received certain medications. - Have certain other types of fungal infections. - Have certain types of cancer. - Have received SCH 56592 within 3 months prior to study entry. - Are pregnant or breast-feeding. - Cannot take medications by mouth. - Are allergic to azole drugs. - Have certain medical conditions. - Have been in this study before.
Total Enrollment: 300
Location and Contact Information:
Univ of Pennsylvania School of Dental Medicine
Philadelphia, Pennsylvania, 19104
United States
Jersey City Med Ctr
Jersey City, New Jersey, 07304
United States
ViRx Inc
San Francisco, California, 94109
United States
Univ of Texas Health Sciences Ctr
San Antonio, Texas, 78284
United States
Queen Elizabeth Hosp Respiratory Unit
St Michael, ,
Barbados
Community Hosp Indianapolis
Indianapolis, Indiana, 46219
United States
TRIAD Health Practice
Chicago, Illinois, 60657
United States
Infectious Disease and AIDS Clinic
Denver, Colorado, 80204
United States
UMDNJ - New Jersey Med School / Cooper Hosp
Camden, New Jersey, 08103
United States
Miami Veterans Administration Med Ctr
Miami, Florida, 33125
United States
Wayne State Univ / Harper Hosp
Detroit, Michigan, 48201
United States
Amelia Ct Clinic
Dallas, Texas, 75235
United States
Med Univ of South Carolina
Charleston, South Carolina, 29425
United States
East Bay AIDS Ctr
Berkeley, California, 94705
United States
Kaiser Foundation Hospital
San Francisco, California, 94118
United States
SUNY / Health Science Ctr at Brooklyn
Brooklyn, New York, 11203
United States
Dupont Circle Physicians Group
Washington D.C., District of Columbia, 200091104
United States
Boulevard Comprehensive Care Ctr
Jacksonville, Florida, 32209
United States
Additional Information:
Study ID Numbers: 305A; C97-331,I97-331
Study Start Date: August 1998
Record last reviewed: February 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002446
Other Hiv Infections Studies:
1. Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
2. A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
3. A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea
4. A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations
5. A Study of Trimetrexate Plus Leucovorin in Children with Pneumocystis Carinii Pneumonia
Related Studies:
Other HIV Infections Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
|
|
|
|
|
|
|
|
